<em>Solanum nigrum</em> Line inhibits osteoclast differentiation and suppresses bone mineral density reduction in the ovariectomy‑induced osteoporosis model

Kim,Jae-Hyun; Shin,Hwajeong; Kim,Minsun; Kim,Sangwoo; Song,Kwangchan; Jung,Hyuk-Sang; Sohn,Youngjoo

doi:10.3892/mmr.2021.12246

Solanum nigrum Line inhibits osteoclast differentiation and suppresses bone mineral density reduction in the ovariectomy‑induced osteoporosis model

Authors:
- Jae-Hyun Kim
- Hwajeong Shin
- Minsun Kim
- Sangwoo Kim
- Kwangchan Song
- Hyuk-Sang Jung
- Youngjoo Sohn
View Affiliations

Affiliations: Department of Anatomy, College of Korean Medicine, Kyung Hee University, Seoul 02‑447, Republic of Korea
Published online on: June 25, 2021 https://doi.org/10.3892/mmr.2021.12246
Article Number: 607
Copyright: © Kim et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Bone homeostasis is maintained by osteoclasts that absorb bone and osteoblasts that form bone tissue. Menopausal osteoporosis is a disease associated with aging and hormonal changes due to menopause causing abnormal activation of osteoclasts, resulting in a decrease in bone density. Existing treatments for osteoporosis have been reported to have serious side effects, such as jawbone necrosis and breast and uterine cancer; therefore, their use by patients is decreasing, whilst studies focusing on alternative treatments are increasingly popular. Solanum nigrum Line (SL) has been used as a medicinal plant that possesses several pharmacological effects, such as anti‑inflammatory and hepatotoxic protective effects. To the best of our knowledge, however, its effects on osteoporosis and osteoclasts have not been demonstrated previously. In the present study, the anti‑osteoporotic effect of SL was investigated using a postmenopausal model of osteoporosis in which Sprague‑Dawley rat ovaries were extracted. In addition, the inhibitory effects on osteoclast differentiation and function of SL was confirmed using an osteoclast model treated with receptor activator of NF‑κB ligand (RANKL) on murine RAW 264.7 macrophages. In vivo experiments showed that SL reduced the decrease in bone mineral density and improved changes in the morphological index of bone microstructure, such as trabecular number and separation. In addition, the number of tartrate resistant acid phosphatase‑positive cells in the femur and the expression levels of nuclear factor of activated T‑cells cytoplasmic 1 (NFATc1) and cathepsin K protein were inhibited. In vitro, SL suppressed RANKL‑induced osteoclast differentiation and bone resorption ability; this was mediated by NFATc1/c‑Fos, a key transcription factor involved in osteoclast differentiation, ultimately inhibiting expression of various osteoclast‑associated genes. These experimental results show that SL may be an alternative treatment for osteoporosis caused by abnormal activation of osteoclasts in the future.

View Figures

View References

1	Sözen T, Özışık L and Başaran NC: An overview and management of osteoporosis. Eur J Rheumatol. 4:46–56. 2017. View Article : Google Scholar
2	Boyle WJ, Simonet WS and Lacey DL: Osteoclast differentiation and activation. Nature. 423:337–342. 2003. View Article : Google Scholar : PubMed/NCBI
3	Teitelbaum SL: Bone resorption by osteoclasts. Science. 289:1504–1508. 2000. View Article : Google Scholar : PubMed/NCBI
4	Tu KN, Lie JD, Wan CKV, Cameron M, Austel AG, Nguyen JK, Van K and Hyun D: Osteoporosis: A Review of Treatment Options. P&T. 43:92–104. 2018.
5	Skjødt MK, Frost M and Abrahamsen B: Side effects of drugs for osteoporosis and metastatic bone disease. Br J Clin Pharmacol. 85:1063–1071. 2019. View Article : Google Scholar
6	Herbology Editorial Committee of Korean Medicine, . Herbology; Younglimsa, Seoul: 2004
7	Youn YN, Lim E, Lee N, Kim YS, Koo MS and Choi SY: Screening of Korean medicinal plants for possible osteoclastogenesis effects in vitro. Genes Nutr. 2:375–380. 2008. View Article : Google Scholar : PubMed/NCBI
8	Ginaldi L, Di Benedetto MC and De Martinis M: Osteoporosis, inflammation and ageing. Immun Ageing. 2:142005. View Article : Google Scholar : PubMed/NCBI
9	Souza PP and Lerner UH: The role of cytokines in inflammatory bone loss. Immunol Invest. 42:555–622. 2013. View Article : Google Scholar : PubMed/NCBI
10	Kim K, Lee SH, Ha Kim J, Choi Y and Kim N: NFATc1 induces osteoclast fusion via up-regulation of Atp6v0d2 and the dendritic cell-specific transmembrane protein (DC-STAMP). Mol Endocrinol. 22:176–185. 2008. View Article : Google Scholar : PubMed/NCBI
11	Kim M, Kim HS, Kim JH, Kim EY, Lee B, Lee SY, Jun JY, Kim MB, Sohn Y and Jung HS: Chaenomelis fructus inhibits osteoclast differentiation by suppressing NFATc1 expression and prevents ovariectomy-induced osteoporosis. BMC Complement Med Ther. 20:352020. View Article : Google Scholar : PubMed/NCBI
12	Zakaria ZA, Gopalan HK, Zainal H, Mohd Pojan NH, Morsid NA, Aris A and Sulaiman MR: Antinociceptive, anti-inflammatory and antipyretic effects of Solanum nigrum chloroform extract in animal models. Yakugaku Zasshi. 126:1171–1178. 2006. View Article : Google Scholar : PubMed/NCBI
13	Zakaria ZA, Sulaiman MR, Morsid NA, Aris A, Zainal H, Pojan NH and Kumar GH: Antinociceptive, anti-inflammatory and antipyretic effects of Solanum nigrum aqueous extract in animal models. Methods Find Exp Clin Pharmacol. 31:81–88. 2009. View Article : Google Scholar : PubMed/NCBI
14	Miyamoto T and Suda T: Differentiation and function of osteoclasts. Keio J Med. 52:1–7. 2003. View Article : Google Scholar : PubMed/NCBI
15	Clohisy JC, Frazier E, Hirayama T and Abu-Amer Y: RANKL is an essential cytokine mediator of polymethylmethacrylate particle-induced osteoclastogenesis. J Orthop Res. 21:202–212. 2003. View Article : Google Scholar : PubMed/NCBI
16	Takayanagi H: The role of NFAT in osteoclast formation. Ann NY Acad Sci. 1116:227–237. 2007. View Article : Google Scholar : PubMed/NCBI
17	Kim JH, Kim EY, Lee B, Min JH, Song DU, Lim JM, Eom JW, Yeom M, Jung HS and Sohn Y: The effects of Lycii Radicis Cortex on RANKL-induced osteoclast differentiation and activation in RAW 264.7 cells. Int J Mol Med. 37:649–658. 2016. View Article : Google Scholar : PubMed/NCBI
18	Lee KY, Kim JH, Kim EY, Yeom M, Jung HS and Sohn Y: Water extract of Cnidii Rhizoma suppresses RANKL-induced osteoclastogenesis in RAW 264.7 cell by inhibiting NFATc1/c-Fos signaling and prevents ovariectomized bone loss in SD-rat. BMC Complement Altern Med. 19:2072019. View Article : Google Scholar : PubMed/NCBI
19	Yeom M, Kim EY, Kim JH, Jung HS and Sohn Y: High doses of Bupleurum falcatum partially prevents estrogen deficiency-induced bone loss with anti-osteoclastogenic activity due to enhanced iNOS/NO signaling. Front Pharmacol. 9:13142018. View Article : Google Scholar : PubMed/NCBI
20	Tschöp MH, Speakman JR, Arch JR, Auwerx J, Brüning JC, Chan L, Eckel RH, Farese RV Jr, Galgani JE, Hambly C, et al: A guide to analysis of mouse energy metabolism. Nat Methods. 9:57–63. 2011. View Article : Google Scholar
21	Chan FK, Moriwaki K and De Rosa MJ: Detection of necrosis by release of lactate dehydrogenase activity. Methods Mol Biol. 979:65–70. 2013. View Article : Google Scholar : PubMed/NCBI
22	Hayman AR: Tartrate-resistant acid phosphatase (TRAP) and the osteoclast/immune cell dichotomy. Autoimmunity. 41:218–223. 2008. View Article : Google Scholar : PubMed/NCBI
23	Campisi A, Acquaviva R, Raciti G, Duro A, Rizzo M and Santagati NA: Antioxidant activities of Solanum Nigrum L. leaf extracts determined in in vitro cellular models. Foods. 8:82019. View Article : Google Scholar : PubMed/NCBI
24	Huang HC, Syu KY and Lin JK: Chemical composition of Solanum nigrum linn extract and induction of autophagy by leaf water extract and its major flavonoids in AU565 breast cancer cells. J Agric Food Chem. 58:8699–8708. 2010. View Article : Google Scholar : PubMed/NCBI
25	Matsubara T, Myoui A, Ikeda F, Hata K, Yoshikawa H, Nishimura R and Yoneda T: Critical role of cortactin in actin ring formation and osteoclastic bone resorption. J Bone Miner Metab. 24:368–372. 2006. View Article : Google Scholar : PubMed/NCBI
26	Burstein AH, Reilly DT and Martens M: Aging of bone tissue: Mechanical properties. J Bone Joint Surg Am. 58:82–86. 1976. View Article : Google Scholar : PubMed/NCBI
27	Osterhoff G, Morgan EF, Shefelbine SJ, Karim L, McNamara LM and Augat P: Bone mechanical properties and changes with osteoporosis. Injury. 47 (Suppl 2):S11–S20. 2016. View Article : Google Scholar : PubMed/NCBI
28	Kalu DN: The ovariectomized rat model of postmenopausal bone loss. Bone Miner. 15:175–191. 1991. View Article : Google Scholar : PubMed/NCBI
29	Kim EY, Kim JH, Kim M, Park JH, Sohn Y and Jung HS: Abeliophyllum distichum Nakai alleviates postmenopausal osteoporosis in ovariectomized rats and prevents RANKL-induced osteoclastogenesis in vitro. J Ethnopharmacol. 257:1128282020. View Article : Google Scholar : PubMed/NCBI
30	Yousefzadeh N, Kashfi K, Jeddi S and Ghasemi A: Ovariectomized rat model of osteoporosis: A practical guide. EXCLI J. 19:89–107. 2020.PubMed/NCBI
31	Taciak B, Białasek M, Braniewska A, Sas Z, Sawicka P, Kiraga Ł, Rygiel T and Król M: Evaluation of phenotypic and functional stability of RAW 264.7 cell line through serial passages. PLoS One. 13:e01989432018. View Article : Google Scholar : PubMed/NCBI
32	Funk JL, Feingold KR, Moser AH and Grunfeld C: Lipopolysaccharide stimulation of RAW 264.7 macrophages induces lipid accumulation and foam cell formation. Atherosclerosis. 98:67–82. 1993. View Article : Google Scholar : PubMed/NCBI
33	Kong L, Smith W and Hao D: Overview of RAW264.7 for osteoclastogensis study: Phenotype and stimuli. J Cell Mol Med. 23:3077–3087. 2019. View Article : Google Scholar : PubMed/NCBI
34	Yeom M, Kim JH, Min JH, Hwang MK, Jung HS and Sohn Y: Xanthii fructus inhibits inflammatory responses in LPS-stimulated RAW 264.7 macrophages through suppressing NF-κB and JNK/p38 MAPK. J Ethnopharmacol. 176:394–401. 2015. View Article : Google Scholar : PubMed/NCBI
35	Collin-Osdoby P and Osdoby P: RANKL-mediated osteoclast formation from murine RAW 264.7 cells. Methods Mol Biol. 816:187–202. 2012. View Article : Google Scholar : PubMed/NCBI
36	Ballanti P, Minisola S, Pacitti MT, Scarnecchia L, Rosso R, Mazzuoli GF and Bonucci E: Tartrate-resistant acid phosphate activity as osteoclastic marker: Sensitivity of cytochemical assessment and serum assay in comparison with standardized osteoclast histomorphometry. Osteoporos Int. 7:39–43. 1997. View Article : Google Scholar : PubMed/NCBI
37	Kim JH and Kim N: Regulation of NFATc1 in osteoclast differentiation. J Bone Metab. 21:233–241. 2014. View Article : Google Scholar : PubMed/NCBI
38	Aliprantis AO, Ueki Y, Sulyanto R, Park A, Sigrist KS, Sharma SM, Ostrowski MC, Olsen BR and Glimcher LH: NFATc1 in mice represses osteoprotegerin during osteoclastogenesis and dissociates systemic osteopenia from inflammation in cherubism. J Clin Invest. 118:3775–3789. 2008. View Article : Google Scholar : PubMed/NCBI
39	Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, Saiura A, Isobe M, Yokochi T, Inoue J, et al: Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell. 3:889–901. 2002. View Article : Google Scholar : PubMed/NCBI
40	Zhao Q, Wang X, Liu Y, He A and Jia R: NFATc1: Functions in osteoclasts. Int J Biochem Cell Biol. 42:576–579. 2010. View Article : Google Scholar : PubMed/NCBI
41	Saftig P, Hunziker E, Wehmeyer O, Jones S, Boyde A, Rommerskirch W, Moritz JD, Schu P and von Figura K: Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci USA. 95:13453–13458. 1998. View Article : Google Scholar : PubMed/NCBI
42	Kim K, Kim JH, Lee J, Jin HM, Lee SH, Fisher DE, Kook H, Kim KK, Choi Y and Kim N: Nuclear factor of activated T cells c1 induces osteoclast-associated receptor gene expression during tumor necrosis factor-related activation-induced cytokine-mediated osteoclastogenesis. J Biol Chem. 280:35209–35216. 2005. View Article : Google Scholar : PubMed/NCBI
43	Wu H, Xu G and Li YP: Atp6v0d2 is an essential component of the osteoclast-specific proton pump that mediates extracellular acidification in bone resorption. J Bone Miner Res. 24:871–885. 2009. View Article : Google Scholar : PubMed/NCBI
44	Han G, Zuo J and Holliday LS: Specialized roles for actin in osteoclasts: Unanswered questions and therapeutic opportunities. Biomolecules. 9:92019. View Article : Google Scholar
45	Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D and Galibert L: A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature. 390:175–179. 1997. View Article : Google Scholar : PubMed/NCBI
46	Matsuo K, Galson DL, Zhao C, Peng L, Laplace C, Wang KZ, Bachler MA, Amano H, Aburatani H, Ishikawa H, et al: Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos. J Biol Chem. 279:26475–26480. 2004. View Article : Google Scholar : PubMed/NCBI
47	David JP, Rincon M, Neff L, Horne WC and Baron R: Carbonic anhydrase II is an AP-1 target gene in osteoclasts. J Cell Physiol. 188:89–97. 2001. View Article : Google Scholar : PubMed/NCBI
48	Kim M, Kim M, Kim JH, Hong S, Kim DH, Kim S, Kim EY, Jung HS and Sohn Y: Crataegus pinnatifida bunge inhibits RANKL-induced osteoclast differentiation in RAW 264.7 cells and prevents bone loss in an ovariectomized rat model. Evid Based Complement Alternat Med. 2021:55215622021. View Article : Google Scholar : PubMed/NCBI
49	Lehenkari P, Hentunen TA, Laitala-Leinonen T, Tuukkanen J and Väänänen HK: Carbonic anhydrase II plays a major role in osteoclast differentiation and bone resorption by effecting the steady state intracellular pH and Ca²⁺. Exp Cell Res. 242:128–137. 1998. View Article : Google Scholar : PubMed/NCBI
50	Manolagas SC: Steroids and osteoporosis: The quest for mechanisms. J Clin Invest. 123:1919–1921. 2013. View Article : Google Scholar : PubMed/NCBI
51	Rochira V, Balestrieri A, Madeo B, Zirilli L, Granata AR and Carani C: Osteoporosis and male age-related hypogonadism: Role of sex steroids on bone (patho)physiology. Eur J Endocrinol. 154:175–185. 2006. View Article : Google Scholar : PubMed/NCBI
52	Tella SH and Gallagher JC: Prevention and treatment of postmenopausal osteoporosis. J Steroid Biochem Mol Biol. 142:155–170. 2014. View Article : Google Scholar : PubMed/NCBI
53	Thulkar J and Singh S: Overview of research studies on osteoporosis in menopausal women since the last decade. J Midlife Health. 6:104–107. 2015.PubMed/NCBI
54	Christensen K, Doblhammer G, Rau R and Vaupel JW: Ageing populations: The challenges ahead. Lancet. 374:1196–1208. 2009. View Article : Google Scholar : PubMed/NCBI
55	Gu XY, Shen XF, Wang L, Wu ZW, Li F, Chen B, Zhang GL and Wang MK: Bioactive steroidal alkaloids from the fruits of Solanum nigrum. Phytochemistry. 147:125–131. 2018. View Article : Google Scholar : PubMed/NCBI
56	Shen KH, Liao AC, Hung JH, Lee WJ, Hu KC, Lin PT, Liao RF and Chen PS: α-Solanine inhibits invasion of human prostate cancer cell by suppressing epithelial-mesenchymal transition and MMPs expression. Molecules. 19:11896–11914. 2014. View Article : Google Scholar : PubMed/NCBI
57	Zhao L, Wang L, Di SN, Xu Q, Ren QC, Chen SZ, Huang N, Jia D and Shen XF: Steroidal alkaloid solanine A from Solanum nigrum Linn. exhibits anti-inflammatory activity in lipopolysaccharide/interferon γ-activated murine macrophages and animal models of inflammation. Biomed Pharmacother. 105:606–615. 2018. View Article : Google Scholar : PubMed/NCBI
58	Lin HM, Tseng HC, Wang CJ, Lin JJ, Lo CW and Chou FP: Hepatoprotective effects of Solanum nigrum Linn extract against CCl(4)-induced oxidative damage in rats. Chem Biol Interact. 171:283–293. 2008. View Article : Google Scholar : PubMed/NCBI
59	Doss HM, Samarpita S, Ganesan R and Rasool M: Ferulic acid, a dietary polyphenol suppresses osteoclast differentiation and bone erosion via the inhibition of RANKL dependent NF-κB signalling pathway. Life Sci. 207:284–295. 2018. View Article : Google Scholar : PubMed/NCBI
60	Shishodia S and Aggarwal BB: Diosgenin inhibits osteoclastogenesis, invasion, and proliferation through the downregulation of Akt, I kappa B kinase activation and NF-kappa B-regulated gene expression. Oncogene. 25:1463–1473. 2006. View Article : Google Scholar : PubMed/NCBI
61	Wu YX, Wu TY, Xu BB, Xu XY, Chen HG, Li XY and Wang G: Protocatechuic acid inhibits osteoclast differentiation and stimulates apoptosis in mature osteoclasts. Biomed Pharmacother. 82:399–405. 2016. View Article : Google Scholar : PubMed/NCBI
62	Kyung TW, Lee JE, Shin HH and Choi HS: Rutin inhibits osteoclast formation by decreasing reactive oxygen species and TNF-alpha by inhibiting activation of NF-kappaB. Exp Mol Med. 40:52–58. 2008. View Article : Google Scholar : PubMed/NCBI